{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=LHRH+Agonist&page=2",
    "query": {
      "intervention": "LHRH Agonist",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 159,
    "total_pages": 16,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=LHRH+Agonist&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=LHRH+Agonist&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-05T01:52:10.621Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04037254",
      "title": "Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Prostate Adenocarcinoma",
        "Stage IIC Prostate Cancer AJCC v8",
        "Stage III Prostate Cancer AJCC v8",
        "Stage IIIA Prostate Cancer AJCC v8",
        "Stage IIIB Prostate Cancer AJCC v8",
        "Stage IIIC Prostate Cancer AJCC v8",
        "Stage IVA Prostate Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Gonadotrophin Releasing Hormone",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Intensity-Modulated Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Niraparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "NRG Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 22,
      "start_date": "2019-10-08",
      "completion_date": "2025-12-23",
      "has_results": true,
      "last_update_posted_date": "2026-07-10",
      "last_synced_at": "2026-10-05T01:52:10.621Z",
      "location_count": 94,
      "location_summary": "Gilbert, Arizona • Tucson, Arizona • Duarte, California + 77 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04037254"
    },
    {
      "nct_id": "NCT01326312",
      "title": "Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "GTx-758 1000mg",
          "type": "DRUG"
        },
        {
          "name": "Lupron Depot",
          "type": "DRUG"
        },
        {
          "name": "GTx-758 2000mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GTx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "80 Years",
        "sex": "MALE",
        "summary": "45 Years to 80 Years · Male only"
      },
      "enrollment_count": 159,
      "start_date": "2011-06",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2023-06-22",
      "last_synced_at": "2026-10-05T01:52:10.621Z",
      "location_count": 36,
      "location_summary": "Phoenix, Arizona • La Mesa, California • Los Angeles, California + 33 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Bernardino",
          "state": "California"
        },
        {
          "city": "Middlebury",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01326312"
    },
    {
      "nct_id": "NCT06922318",
      "title": "The COSMYC Trial (COmbined Suppression of MYC)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Castration-resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "ZEN-3694",
          "type": "DRUG"
        },
        {
          "name": "Testosterone cypionate",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Luteinizing hormone-releasing hormone (LHRH) analogue",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 50,
      "start_date": "2025-08-19",
      "completion_date": "2031-08-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-18",
      "last_synced_at": "2026-10-05T01:52:10.621Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06922318"
    },
    {
      "nct_id": "NCT03419234",
      "title": "Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Castration Levels of Testosterone",
        "Castration-Resistant Prostate Carcinoma",
        "Metastatic Prostate Carcinoma in the Soft Tissue",
        "Prostate Carcinoma Metastatic in the Bone",
        "Stage IV Prostate Adenocarcinoma AJCC v7"
      ],
      "interventions": [
        {
          "name": "Abiraterone Acetate",
          "type": "DRUG"
        },
        {
          "name": "Androgen deprivation therapy",
          "type": "DRUG"
        },
        {
          "name": "Cabazitaxel",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ECOG-ACRIN Cancer Research Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 223,
      "start_date": "2018-04-26",
      "completion_date": "2028-04-01",
      "has_results": true,
      "last_update_posted_date": "2026-08-06",
      "last_synced_at": "2026-10-05T01:52:10.621Z",
      "location_count": 665,
      "location_summary": "Fairbanks, Alaska • Goodyear, Arizona • Kingman, Arizona + 437 more",
      "locations": [
        {
          "city": "Fairbanks",
          "state": "Alaska"
        },
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Kingman",
          "state": "Arizona"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03419234"
    },
    {
      "nct_id": "NCT02357654",
      "title": "GnRH for Luteal Support in IVF/ICSI/FET Cycles",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Infertility"
      ],
      "interventions": [
        {
          "name": "GnRH",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University Reproductive Associates",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 40 Years · Female only"
      },
      "enrollment_count": 350,
      "start_date": "2015-11",
      "completion_date": "2026-07",
      "has_results": false,
      "last_update_posted_date": "2026-07-09",
      "last_synced_at": "2026-10-05T01:52:10.621Z",
      "location_count": 1,
      "location_summary": "Hasbrouck Heights, New Jersey",
      "locations": [
        {
          "city": "Hasbrouck Heights",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02357654"
    },
    {
      "nct_id": "NCT04964934",
      "title": "Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "ER-Positive HER2-Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "AZD9833",
          "type": "DRUG"
        },
        {
          "name": "AZD9833 Placebo",
          "type": "DRUG"
        },
        {
          "name": "Anastrozole",
          "type": "DRUG"
        },
        {
          "name": "Anastrozole placebo",
          "type": "DRUG"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        },
        {
          "name": "Letrozole placebo",
          "type": "DRUG"
        },
        {
          "name": "Palbociclib",
          "type": "DRUG"
        },
        {
          "name": "Abemaciclib",
          "type": "DRUG"
        },
        {
          "name": "Luteinizing hormone-releasing hormone (LHRH) agonist",
          "type": "DRUG"
        },
        {
          "name": "Ribociclib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 315,
      "start_date": "2021-06-30",
      "completion_date": "2028-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-23",
      "last_synced_at": "2026-10-05T01:52:10.621Z",
      "location_count": 64,
      "location_summary": "Phoenix, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 56 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04964934"
    },
    {
      "nct_id": "NCT02023463",
      "title": "Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adenocarcinoma of the Prostate",
        "Recurrent Prostate Cancer",
        "Stage IIB Prostate Cancer",
        "Stage III Prostate Cancer",
        "Stage IV Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Goserelin acetate",
          "type": "DRUG"
        },
        {
          "name": "Leuprolide acetate",
          "type": "DRUG"
        },
        {
          "name": "Radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 25,
      "start_date": "2014-04-02",
      "completion_date": "2040-01-01",
      "has_results": false,
      "last_update_posted_date": "2025-11-25",
      "last_synced_at": "2026-10-05T01:52:10.621Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02023463"
    },
    {
      "nct_id": "NCT01546987",
      "title": "Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "GnRH agonist",
          "type": "DRUG"
        },
        {
          "name": "Anti-androgen",
          "type": "DRUG"
        },
        {
          "name": "TAK-700",
          "type": "DRUG"
        },
        {
          "name": "Radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Radiation Therapy Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 239,
      "start_date": "2012-05",
      "completion_date": "2025-09-04",
      "has_results": true,
      "last_update_posted_date": "2026-03-06",
      "last_synced_at": "2026-10-05T01:52:10.621Z",
      "location_count": 165,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 136 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Auburn",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01546987"
    },
    {
      "nct_id": "NCT01076335",
      "title": "Neoadjuvant Hormones + Docetaxel in Node-Positive Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Neoadjuvant Hormonal Therapy",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": 40,
      "start_date": "2005-05",
      "completion_date": "2015-06",
      "has_results": true,
      "last_update_posted_date": "2016-09-19",
      "last_synced_at": "2026-10-05T01:52:10.621Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01076335"
    },
    {
      "nct_id": "NCT04711252",
      "title": "A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "ER-Positive HER2-Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "AZD9833",
          "type": "DRUG"
        },
        {
          "name": "Anastrozole",
          "type": "DRUG"
        },
        {
          "name": "Anastrozole placebo",
          "type": "DRUG"
        },
        {
          "name": "AZD9833 placebo",
          "type": "DRUG"
        },
        {
          "name": "Palbociclib",
          "type": "DRUG"
        },
        {
          "name": "Luteinizing hormone-releasing hormone (LHRH) agonist",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 1371,
      "start_date": "2021-01-28",
      "completion_date": "2029-02-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-28",
      "last_synced_at": "2026-10-05T01:52:10.621Z",
      "location_count": 30,
      "location_summary": "Mobile, Alabama • Springdale, Arkansas • Harbor City, California + 25 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Harbor City",
          "state": "California"
        },
        {
          "city": "Solvang",
          "state": "California"
        },
        {
          "city": "Lone Tree",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04711252"
    }
  ]
}